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1035-216 Mitral Valve Dynamics With Different Pacing Sites
Frank Langer, Frederick A. Tibayan, Filiberto Rodriguez, Tomasz Timek, Mary K. Zasio, 
David Liang, George T. Daughters, Neil B. Ingels, D. Craig Miller, Stanford University, 
Stanford, CA, Palo Alto Medical Foundation, Stanford, CA
Background: The influence of pacing site on 3-D annular/leaflet dynamics and mitral val-
vular function is incompletely understood.
Methods: Eight adult sheep underwent surgical insertion of radiopaque markers on the
LV, mitral annulus and mitral leaflets. Hemodynamic and 3-D marker dynamics were
studied one week later with biplane 60Hz videofluoroscopy during atrial (pacing site=left
atrium, 115 min-1) and A-V-sequential pacing (140ms interval) with three epicardial ven-
tricular pacing sites: apical RV, RVOT and antero-lateral LV wall
Results: Compared with atrial pacing: 1.) LV-AV-pacing delayed valve closure (time from
ED to minimum distance between opposing leaflet edge markers) at leaflet center and
anterior (ACOM) and posterior commissures (PCOM); 2.) Leaflet angle (angle between
leaflet center edge marker and annular plane) at ED was significantly greater with LV-AV-
pacing; 3.) Regurgitant fraction ((LVEDV – LV volume at leaflet closure) / SV) was
increased with LV-AV-pacing.
Conclusions: AV-sequential-pacing with the antero-lateral LV epicardium as pacing site
produced more widely open leaflets at ED and delayed mitral valve closure resulting in
pacing-induced mitral regurgitation. Such changes in the mitral valvular apparatus have
potential clinical implications since the LV has become a popular pacing site with the
advent of transcoronary venous leads. 
*p<0.05 vs. atrial pacing RM ANOVA, Dunnett’s post hoc test
1035-217 Cardiac Contractility Modulation by Nonexcitatory 
Electrical Currents for Treating Systolic Heart Failure 
Early Multicenter Experience
Giuseppe Augello, Carlo Pappone, Salvatore Rosanio, Gabriele Vicedomini, Eustachio 
Agricola, Simone Sala, Yuval Mika, Michael Wolzt, Gunter Stix, Herwig Schmidinger, 
Vita-Salute San Raffaele University Hospital, Milan, Italy
Background — Cardiac contractility modulation (CCM) by means of non-excitatory cur-
rents delivered during action potential plateau, has been shown to acutely enhance sys-
tolic function in humans with HF.
Objective — To report on our early multicenter experience of chronic safety and func-
tionality of this novel form of electrical therapy.
Methods — Thirteen patients with drug-resistant HF (NYHA class III) were consecutively
implanted with a device (OPTIMIZER IITM) delivering CCM biphasic square-wave pulses
(20ms, 5.8 to 7.7V, 30ms after detection of local activation) through two right ventricular
leads screwed-in the right aspect of the interventricular septum. CCM signals were deliv-
ered 3 hours daily over 8 weeks (3hr phase) and 7 hours daily over the next 16 weeks
(7hr phase). Safety and feasibility of this novel therapy were regarded as primary end-
points. Preliminary clinical efficacy was assessed at baseline, and at the end of each
phase.
Results — At the end of follow-up all patients were alive, without heart transplantation or
left ventricular assist device Serial 24-h Holter analysis revealed no major arrhythmias in
any patients. No device failed for reason other than end of battery life. During the 3hr
phase EF improved from 22.7±7% to 28.7±7% (P=0.01), 6-MWT from 454±103m to
486±96m (P<0.01), MLHFQ from 36±21 to 18±11 (P=0.01) and NYHA class from 3 to
1.8 (P=0.01). CCM delivery 7 hours daily caused a further improvement in EF (from
28.7±7.% to 35±12.3%, P=0.01), 6-MWT (from 486±96m to 498±112m, P=0.06),
MLHFQ from 18±11 to 9±5 (P<0.01) and NYHA functional class (from 1.8 to 1.5,
P=0.04). Use and dosage of inotropic and diuretic agents were reduced in both phases.
Conclusions— CCM therapy appears to be safe and feasible. Proarrhythmic effects of
this novel therapy seem unlikely. Preliminary data indicate that CCM gradually and signif-
icantly improves systolic performance, symptoms and functional status. CCM therapy for
7 hours/d is associated with greater dispersion near the mean, emphasizing the need for
individually tailoring CCM delivery duration. Controlled randomized studies are needed to
validate this novel concept.
1035-218 The Monolithic Fetal Pacemaker III: Device Dimensions 
by Fetal Ultrasonography
Evgueni Fayn, Daniel H. Zavitz, Vicki L. Mahan, Howard A. Chou, DaeGyun Park, Bettina 
F. Cuneo, Marc Ovadia, University of Illinois, Chicago, IL, Advocate Christ Medical 
Center, Oak Lawn, IL
Background Complete heart block in utero has a high fatality when associated with
hydrops fetalis. We have developed a design for closed thorax, closed maternal abdomen
over-the-wire placement of a unipolar monolithic pacemaker whose power source and
anode reside in amniotic space and whose cathode resides in the left pleural space in
direct apposition to the fetal pericardium. Pacing occurs through the pericardium with cur-
rent passage through the fetal skin.
Objectives and Methods: Device prototyping requires measurement of the distance
from amniotic space to pleural space along the axis of deployment. 250 Fetal ultrasound
studies were reviewed for this measurement as well as for femur length, biparietal diame-
ter, and abdominal circumference to allow estimation of gestational age. This was IRB
approved
Results: 80 human fetal studies were adequate for all measurements. Gestational age
ranged from 17 to 33 weeks. At 19 weeks the amniotic-to-pleural distance measured 13.9
+/- 3.2 mm, at 20 weeks 13.2 +/- 2.8 mm and at 21 weeks 15.6 +/- 2.2. After this time
wide range of dimension precluded identifying an optimal distance
In conclusion, the optimal shaft length is 14.5 mm for monolithic fetal pacemaker device
deployment at 19-20 weeks. This time of deployment will allow 2-4 weeks for resolution of
hydrops prior to achieving viability at 24 weeks. A single device size will support most
hdropic fetuses in the window leading to viability, a larger device being necessary post
fetal surgery Support NIH HHS 1R43 HL 67520-01
1035-219 The L-Type Calcium and Sarcolemmal KATP Channels 
May Contribute to Pacing-Induced Cardioprotection
Philippe Bruchez, Antonio Rosa, Lukas Kappenberger, Eric Raddatz, Institute of 
Physiology, Lausanne, Switzerland, University Hospital, Lausanne, Switzerland
Background: Chronic ventricular pacing has been shown to induce post-hypoxic cardio-
protection. We hypothesized that L-type Ca++ channel, sarcolemmal (sarcKATP) and
mitochondrial KATP (mitoKATP) channels could be involved in this protection.
Methods: Hearts of 4-day-old chick embryos were paced in ovo during 12 h using asyn-
chronous and intermittent ventricular stimulation (5 min ON - 10 min OFF) at 110% of the
intrinsic rate. Sham operated and paced hearts were then submitted in vitro to normoxia
(30min), anoxia (30min) and reoxygenation (60min). L-type Ca++ channel agonist BAY K
8644 (BAY, 1µM) or blocker verapamil (Verap, 10nM), nonselective KATP channel antag-
onist glibenclamide (Glib, 10µM), mitoKATP channel agonist diazoxide (DIAZO, 100µM)
or antagonist 5-hydroxydecanoate (5-HD, 500µM) were used in the sham and paced iso-
lated hearts (n= 4). ECG and atrial and ventricular contractions were continuously
recorded during experiments. Reoxygenation-induced chrono-, dromo- and inotropic dis-
trurbances, arrhythmias and alterations of electromechanical delay (EMD) in atrium and
ventricle were investigated.
Results: Under normoxia, heart rate (170±19 bpm), PR interval (88±21 ms), atrio-ventric-
ular propagation (28±5 mm/s), ventricular shortening velocity (5.7±1 mm/s), atrial EMD
(17±2 ms) and ventricular EMD (17±2 ms) (mean±SD) were stable and similar in the
untreated sham and paced groups. None of the tested agents influenced these baseline
parameters, except BAY which increased ventricular EMD by 34% in sham hearts. Dur-
ing reoxygenation, incidence of arrhythmias was lower and ventricular EMD recovered
faster in paced hearts than in sham hearts. In sham hearts, BAY (but not Verap) or Glib
(but neither 5-HD nor DIAZO) accelerated recovery of ventricular EMD, reproducing the
pacing-induced protection. By contrast, none of these agents improved functional recov-
ery of the paced hearts.
Conclusion: Pacing may induce a moderate increase in intracellular Ca++ through subtle
activation of L type Ca++ channels and/or inhibition of sarcKATP channels, improving
specifically ventricular excitation-contraction coupling during reoxygenation. Supported
by the Swiss Cardiology Foundation
Control: 
atrial 
pacing
RVapex-AV-
sequential 
pacing
RVOT-AV-
sequential 
pacing
LV-AV-
sequential 
pacing
Valve closure @ 
ACOM (ms)
27.1 ± 9.4 43.8 ± 8.9 37.6 ± 6.1 48.0 ± 8.0 *
Valve closure @ 
leaflet center (ms)
20.9 ± 10.3 35.5 ± 8.0 35.5 ± 6.6 52.2 ± 4.9 *
Valve closure @ 
PCOM (ms)
16.7 ± 10.0 23.0 ± 3.1 25.1 ± 7.1 45.9 ± 7.6 *
Anterior leaflet 
angle (°) @ ED
31.9 ± 1.8 39.4 ± 2.0 36.6 ± 2.1 41.3 ± 3.8 *
Posterior leaflet 
angle (°) @ ED
55.5 ± 3.9 61.6 ± 4.1 * 58.8 ± 3.8 62.2 ± 3.2 *
Regurgitant 
fraction (% SV)
5.5 ± 2.8 7.0 ± 1.7 9.8 ± 2.4 13.3 ± 2.6 *
